About Vir Biotechnology
Vir Biotechnology is a publicly listed company based in San Francisco (United States) founded in 2017 by Klaus Frueh. Vir Biotechnology has raised $216 million across 4 funding rounds from investors including Gates Foundation, Arch Venture Partners and GSK. The company has 408 employees. Vir Biotechnology has completed 2 acquisitions, including Agenovir and TomegaVax. Its chief executive, as recorded, is George Scangos. Its website vir.bio draws about 30 thousand monthly visits. Vir Biotechnology offers products and services including Antibody Platform and PRO-XTENâ„¢ Masking Technology. Its focus areas include Life Sciences, Immunotherapy, Diversified and Infectious Diseases. Its legal entity is Vir Biotechnology, Inc. Its competitors include BeiGene, Vaxcyte and StrideBio; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for the treatment of infectious diseases. The companys approach is focused on immune programming to manipulate pathogen-host interactions. The company has developed drugs for Covid-19, HBV, HIV, and influenza-A.
- Annual Revenue$68.56 M (USD)-7.61as on Dec 31, 2025
- Net Profit-$437.99 M (USD)16.09as on Dec 31, 2025
- EBITDA-$456.34 M (USD)10.32as on Dec 31, 2025
- Total Equity Funding$216M (USD)
in 4 rounds
- Latest Funding Round$32.44M (USD), Post-IPO
May 2020
- InvestorsGates Foundation
& 2 more
- Employee Count408
- Investments & AcquisitionsAgenovir
& 1 more
Products & Services of Vir Biotechnology
Vir Biotechnology offers a comprehensive portfolio of products and services, including Antibody Platform and PRO-XTEN™ Masking Technology.
Platform for discovering and optimizing antibody-based medicines for diseases.
Technology for masking and releasing treatments in infectious diseases and cancer.
Funding Insights of Vir Biotechnology
Vir Biotechnology has successfully raised a total of $216M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $32.44 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $216M
- Total Rounds 4
- Last Round Post-IPO — $32.44M
- First Round $150M
(Sep 2017)
- Investors Count 3
All 4 funding rounds of Vir Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2020 | $32.44M | Post-IPO | – | – | – |
| Apr 2020 | $250M | Post-IPO | – | – | |
| Jun 2018 | $66M | Series A | – | – | – |
| Sep 2017 | $150M | Series A | – | Arch Venture Partners, Gates Foundation | – |
3 investors in total: 3 institutional.
Investors in Vir Biotechnology
Vir Biotechnology has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Arch Venture Partners and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Vir Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vir Biotechnology
93 people are tracked at Vir Biotechnology (61 in leadership, 8 in board & advisors, 24 in team); the tracked headcount is 408.
| Name | Role | Group |
|---|---|---|
Klaus Frueh | Co-Founder | Leadership |
George Scangos | CEO | Leadership |
Dezz Ropp | Vice President, Program And Portfolio Management | Leadership |
Jacqueline McBride | Vice President, Translational Biology At Vir Biotechnology, Inc. | Leadership |
Maryam Sadat | Senior Vice President Quality, EHS & Lab Ops | Leadership |
Tyler Chuang | Associate Director, Research Strategic Planning And Operations | Leadership |
Vladimir N. Podust | Senior Director, Analytical And Formulation Development / QC Oncology | Leadership |
Sandy Deveze | Head Of Clinical Data Management | Leadership |
James L. | Senior Director, Tax | Leadership |
Grace Jiang | Head Of Regulatory Affairs, Oncology, VP | Leadership |
Cailey Ruth | Director | Leadership |
Maribel Reyes | Vp, Clinical Pharmacology | Leadership |
Amy Rock | Senior Vice President, Regulatory Affairs | Leadership |
Kevin Anglim | Director, Compensation | Leadership |
Tim Hwang | Vice President, Human Resources | Leadership |
Leah Anderson Gaffney | Director Clinical Research | Leadership |
Hung Truong | Associate Director, Procurement Research Lead | Leadership |
Marianne De Backer | CEO | Leadership |
Mimmi Ballard | Director, Analytical Development And Quality Control, Bioassays | Leadership |
Jeff Calcagno | Executive Vice President & Chief Business Officer | Leadership |
73 more people are available in the full profile.
Complete people profiles for Vir Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vir Biotechnology
Vir Biotechnology is a publicly listed company on the NASDAQ with ticker symbol VIR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Oct 2019
- Listed onNASDAQ: VIR
- Listed entityVir Biotechnology, Inc.
- Exchange sectorHealth technology
- ISINUS92764N1028
- Share price$10.61 (-6.11% on the day) · 2026-10-13
- Market capitalisation$1.80B
- EPS (diluted, trailing year)$-1.86
- Volume (last session)1,783,881
Financials of Vir Biotechnology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $68.6M | -$438.0M | -$456.3M |
| 2024 | $74.2M | -$522.0M | -$508.9M |
| 2023 | $86.2M | -$615.1M | -$641.5M |
| 2022 | $1.62B | $515.8M | $848.6M |
| 2021 | $1.10B | $528.6M | $432.7M |
Detailed financial statements for Vir Biotechnology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vir Biotechnology
Vir Biotechnology has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Agenovir and TomegaVax.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antiviral therapeutics are developed using nuclease-based technologies for infectious diseases. | agenovir.com | San Francisco, United States | 2014 | May 2018 | •••• | |
Developing cytomegalovirus-vector based vaccines for viral infections | tomegavax.com | Beaverton, United States | 2011 | Jan 2017 | •••• |
Complete acquisition details for Vir Biotechnology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Vir Biotechnology
6 dated milestones of Vir Biotechnology across 3 years, from founding to its latest funding, stage changes and deals.
Competitors of Vir Biotechnology
Vir Biotechnology has 3 listed competitors in our database, 3 of them funded. They include BeiGene, Vaxcyte and StrideBio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. |
Detailed competitors of Vir Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vir Biotechnology
The website of Vir Biotechnology (vir.bio) receives about 29.8K visits a month and ranks #1,332,196 among all websites worldwide, #1,723 in Biotechnology and Pharmaceuticals.
- Monthly visits29.8K
▲ 57.7% vs previous month
- Unique visitors8K
per month
- Global rank#1,332,196
among all websites
- Category rank#1,723
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.1
- Average visit55 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Vir Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| astellasgenetherapies.com | 100% | 1K | View details | ||
| aligos.com | 99% | 3.4K | #3,982,602 | View details | |
| assemblybio.com | 99% | 5.8K | #3,402,677 | View details | |
| mbcbiolabs.com | 98% | #2,013,343 | View details | ||
| allogene.com | 98% | 33.5K | #1,405,171 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 37 similar websites and full traffic analytics for Vir Biotechnology
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 37 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Vir Biotechnology (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vir Biotechnology
Complete news archive for Vir Biotechnology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vir Biotechnology
Vir Biotechnology was founded in 2017.
Vir Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
George Scangos is the CEO of Vir Biotechnology, as recorded in our data.
Vir Biotechnology is a funded company, having raised a total of $216M across 4 funding rounds to date. The company's 1st funding round was a Series A of $150M, raised on Sep 2017.
Vir Biotechnology has 408 employees.
Annual revenue of Vir Biotechnology is $68.56M as on Dec 31, 2025.
Developer of therapeutics for the treatment of infectious diseases. The companys approach is focused on immune programming to manipulate pathogen-host interactions. The company has developed drugs for Covid-19, HBV, HIV, and influenza-A.
Vir Biotechnology offers Antibody Platform and PRO-XTENâ„¢ Masking Technology.
Yes, Vir Biotechnology is publicly traded on NASDAQ under the ticker symbol VIR.
Vir Biotechnology has 3 investors. Key investors include Gates Foundation, Arch Venture Partners, and GSK.